UCB (OTCMKTS:UCBJF) Shares Gap Up – What’s Next?

UCB SA (OTCMKTS:UCBJF) shares gapped up prior to trading on Wednesday . The stock had previously closed at $280.07, but opened at $315.09. UCB shares last traded at $315.09, with a volume of 139 shares traded.

Wall Street Analysts Forecast Growth

A number of research firms have commented on UCBJF. Deutsche Bank Aktiengesellschaft restated a “buy” rating on shares of UCB in a research report on Monday, December 8th. The Goldman Sachs Group reiterated a “buy” rating on shares of UCB in a research note on Monday, February 16th. Barclays reissued an “overweight” rating on shares of UCB in a report on Tuesday, January 6th. Wolfe Research began coverage on UCB in a report on Monday, February 23rd. They set an “outperform” rating for the company. Finally, Stephens reiterated an “overweight” rating on shares of UCB in a research report on Thursday, January 15th. Six equities research analysts have rated the stock with a Buy rating, According to MarketBeat.com, the stock has an average rating of “Buy”.

UCB Price Performance

The company has a quick ratio of 0.78, a current ratio of 1.19 and a debt-to-equity ratio of 0.33. The business’s fifty day moving average is $308.55 and its two-hundred day moving average is $282.62.

UCB Company Profile

UCB SA is a Belgium-based biopharmaceutical company focused on the discovery, development and commercialization of treatments for severe diseases of the immune system and the central nervous system. Founded in 1928 as Union Chimique Belge, the company transitioned from chemicals into pharmaceuticals and biologics and today concentrates its efforts on specialty medicines and research-driven innovation. UCB’s work spans small molecules and biologics, with an emphasis on improving outcomes for patients with chronic and complex conditions.

Key therapeutic areas for UCB include immunology and neurology, where the company markets several well-known products and maintains an active clinical pipeline.